Ciencias de la Salud

URI permanente para esta comunidadhttp://repositorio.uta.edu.ec/handle/123456789/813

Examinar

Resultados de la búsqueda

Mostrando 1 - 2 de 2
  • Item type:Ítem,
    CANNABIDIOL COMO TERAPIA ALTERNATIVA EN EL TRATAMIENTO DE EPILEPSIA REFRACTARIA EN PACIENTES PEDIÁTRICOS
    (2025-10-15)
    Calucho Aguilar, Diego Leonardo
    ;
    Paredes Lascano, Patricia Lorena
    ;
    Universidad Técnica de Ambato / Facultad de Ciencias de Salud / Carrera de Medicina
    Introduction: Refractory epilepsy, present in 30% of pediatric patients, represents a significant clinical challenge. Cannabidiol (CBD) has been proposed as a promising therapeutic alternative. Objective: To analyze the available evidence on the efficacy and safety of CBD in the treatment of refractory epilepsy in pediatric patients through a systematic literature review. Methods: A systematic review was conducted following PRISMA guidelines. PubMed/MEDLINE and Scopus databases were searched to identify studies published between January 2020 and September 2024. Randomized con-trolled trials and observational studies evaluating the efficacy and/or safety of CBD in pediatric pa-tients with refractory epilepsy were included. Results: Nine studies meeting the selection criteria were included. The findings indicate a significant reduction in seizure frequency in 56–78% of patients treated with CBD, with some studies reporting seizure frequency reductions exceeding 50%. Efficacy was sustained over follow-up periods of up to 156 weeks. CBD demonstrated a favorable safety pro-file, with adverse events generally mild to moderate, including drowsiness, decreased appetite, and diarrhea. Several studies reported improvements in patients’ quality of life and cognitive functioning, assessed using standardized tools. Conclusions: Current evidence suggests that CBD may be an effective and safe therapeutic option for the treatment of refractory epilepsy in pediatric patients. Further studies are needed to establish optimal dosing protocols andevaluate long-term effects.
  • Item type:Ítem,
    DOLOR CRÓNICO Y SU ABORDAJE CON CANNABIDIOL: UNA OPCIÓN TERAPÉUTICA
    (Universidad Técnica de Ambato/ Facultad de Ciencias de Salud /Carrera de Medicina, 2024-09-25)
    Vega Cueva, John Omar
    ;
    Salinas Velastegui, Verónica Gabriela
    Introduction: chronic pain is a health problem that affects millions of people in the world, generating an important biopsychosocial problem, which is why there are several types of therapeutic approaches, such as the use of cannabidiol for its anti-inflammatory, analgesic and neuroprotective qualities. Objectives: perform a bibliographic review on cannabidiol and how this active ingredient is a treatment option for chronic pain.Materials and methods: a search on cannabidiol as a treatment for chronic pain was carried out in several databases such as: Medline/PubMed, LILACS-BIREME and SciELO, including inclusion and exclusion criteria of the reviewed articles.Results: chronic pain is a condition that is characterized by the persistence of pain for more than 3 months, affecting quality of life and whether or not it is associated with true tissue damage. Worldwide, it affects more than 2 billion people and in Ecuador, about 21% of the population suffers from this pathology. Chronic pain can be of various types such as: neuropathic pain, nociceptive pain, centralized pain, mixed pain and idiopathic pain, which have unique characteristics that allow their differentiation.Cannabidiol has been involved in severalinvestigations to treat chronic pain. This is a chemical compound found in the cannabis plant, along with another variety of so-called cannabinoids, such as tetrahydrocannabidiol (THC), which is characterized by its effects. psychoactive, while cannabidiol lacks them. Generally speaking, cannabidiol acts on the body's endocannabinoid system, which regulates pain, immune function, etc. For this reason, it is believed that cannabidiol can reduce pain and inflammation. Although there is no minimum or maximum dose of cannabidiol to treat chronic pain, it can vary from 10 mg to 6000 mg. Therefore, strengthening research regarding cannabidiol as a therapy for chronic pain is vital to determine if it can be an alternative to the classic treatments that exist for chronic pain.Conclusions: several investigations have been carried out regarding the use of cannabidiol independently as a therapy for the treatment of pain, where no clear results have been found regarding the effectiveness of this medication, in additionto the fact that the result found will depend on the dosage. given to the population that has undergone this treatment scheme.